TPC3: COST OF AML TREATMENT IN BELGIUM: RESULTS OF A RANDOMIZED TRIAL WITH AND WITHOUT FILGRASTIM USE  by Noens, L et al.
Abstracts 379
OBJECTIVES: To compare the direct medical costs asso-
ciated with two different regimens for the treatment of
Helicobacter pylori-related peptic ulcer disease (PUD)
from a hospital perspective. The efficacy of a new regimen,
including ranitidine bismuth citrate, amoxycillin and cla-
rithromycin (RAC), was recently compared in a study at a
local teaching hospital with that of a regimen consisting of
omeprazole, amoxycillin and clarithromycin (OAC). The
study results showed no significant difference in the effi-
cacy of the two regimens, but the cost implication of the
two regimens was not examined. The drug cost of OAC
(HK$364, $US  7.8HK) was 20% more than that of
RAC (HK$304) for a 7-day therapy.
METHOD: Data from a controlled, randomized clinical
trial conducted in Hong Kong was reanalyzed. The
records of 100 patients with Helicobacter pylori-related
PUD, who were previously randomized to receive either
RAC or OAC, were reviewed. The hospital resources con-
sumed during the period of PUD treatment were retrieved
and studied. The total cost associated with each regimen
per ulcer-healed patient was calculated and analyzed.
RESULTS: Twelve of the 100 patients were excluded from
the analysis because of incomplete documentation or non-
compliance with the protocol of the clinical trial. Forty-
one inpatients and 47 outpatients were included in the
analysis. In the inpatient group, there was no significant
difference between the median direct cost associated with
OAC and RAC ($13,042 and $11,622, respectively; P 
0.168). In the outpatient group, the median direct cost as-
sociated with RAC was significantly lower than that of
OAC ($4,096 and $3,839, respectively; P  0.003).
CONCLUSION: The direct medical costs associated with
OAC and RAC were similar for inpatient treatment of
Helicobacter pylori-related PUD but RAC was less costly
in the outpatient setting.
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INTRODUCTION: A randomised multi-centre phase III
trial using Filgrastim (5 g/kg/day until neutrophil recov-
ery) in induction and consolidation therapy for ‘de novo’
adult acute myeloid leukaemia (AML) patients showed
safety and efficacy of the drug with significant reduction in
hospital duration and IV anti-infective drug therapy (Heil
et al, Blood, 1997, 90, 4710–4718).
OBJECTIVE: Considering the Belgium patients enrolled
in the trial to estimate the financial impact of Filgrastim
use in the treatment of AML for that country.
METHODS: Retrospective data collection of resource use
was obtained from the 36 Belgian patients (20 cases and
16 controls) enrolled through 3 hospitals. The data were
retrieved from Case Report Forms and hospital bills. The
cost perspective considered is the reimbursement authority
of Belgium. A cost-minimisation model is developed in-
cluding the following resource items: hospital duration, IV
anti-infective drug days, lab test days, blood transfusion
units, vials of Filgrastim, other drug use excluding chemo-
therapy, and use of other diagnostic tests (Rx, Scans). Unit
costs in 1998 BEF are retrieved from the reimbursement
authority (RIZIV/INAMI), the Red Cross Blood Bank, the
database of the Belgium Pharmaceutical Association (APB),
and a private database on cost of health care in Belgium
hospitals (CECODI).
RESULTS: The cost model shows an average cost decrease
of 73.31 BEF (5,7%) per patient for induction and consol-
idation therapy with Filgrastim. Sensitivity analysis on
hospital day costs that may widely vary, shows a break-
even point reached at a cost per day much lower than the
minimum reimbursement cost (break-even point  952
BEF).
CONCLUSIONS: Filgrastim use in the treatment of AML
patients in Belgium is likely to induce cost savings. The
cost results are conservative estimates that do not include
indirect cost evaluations and quality of life improvement
of the patient due to earlier hospital discharge.
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OBJECTIVE: To evaluate the economic implications of
amlodipine therapy in patients with advanced left ventric-
ular dysfunction due to nonischemic dilated cardiomyopa-
thy by using data from the Prospective Randomized Amlo-
dipine Survival Evaluation (PRAISE).
METHODS: By using a decision analytic model, costs and
effects were estimated for the first 2 years of observation in
PRAISE and were projected for 30 years after initiation of
therapy (referred to as the lifetime projection).
RESULTS: While statistical tests of the survival curves
indicated that amlodipine significantly improved survival
(P  0.001), differences in life expectancy (amlodipine,
0.19 years (95% CI, 0.03 to 0.41 years during the first
2 years of the trial; 2.89 years, 95% CI, 0.37 to 6.14
years projected for the patient’s lifetime) were not signifi-
cant. The ratios of cost per year of life saved were
$8000; those of cost per quality-adjusted year of life
saved were $14,300. The confidence intervals for the
cost-effectiveness ratios indicated that for the first 2 years
of the trial, amlodipine was unlikely to have ratios
